Preventing Bleeding in Stem Cell Transplant
Part of Blood & lymphatic clinical trials.
This trial tests if a medication called etamsylate can help prevent bleeding in patients getting a stem cell transplant. If your platelet count drops very low after transplant, this drug may reduce your risk of bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a blood disease that requires a stem cell transplant.
- Your doctor expects your platelet count to stay very low (10 or lower) for at least 5 days after transplant.
- You have normal blood clotting function, good liver, kidney, and heart function.
- You do not have active bleeding, infection, or a bleeding disorder.
- You are not pregnant or breastfeeding, and you agree to use effective birth control if you can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a one-time infusion of umbilical cord blood cells can safely raise platelet counts in people whose counts dropped after cancer treatment. It is for patients whose low platelets are clearly linked to their cancer therapy and who have no other major health problems.
This trial tests a drug called avatrombopag (a pill) to help raise platelet counts in people who develop very low platelets after a stem cell transplant from a half-matched donor (haplo-HSCT). It aims to see if the drug is safe and effective at reducing the need for platelet transfusions.
This trial is for people with certain blood cancers or bone marrow disorders who need a stem cell transplant from a half-matched donor. It compares two different doses of a medicine that helps prevent the donor cells from attacking the body (graft-versus-host disease).
This study uses a special blood test to create a score that predicts bleeding risk in patients with blood cancers and very low platelet counts. It could help doctors decide if you need extra care to prevent bleeding.
This early-phase trial tests a medication to prevent rejection of donated stem cells in children. It's for patients who are at high risk for their transplant to fail.
This trial compares two drugs, romiplostim and rhTPO, to help increase platelet counts after a stem cell transplant in people with MDS or aplastic anemia. The goal is to see which drug works better at reducing the need for platelet transfusions.
Hear when a new Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.